Dr. Deisher will be presenting, at the invitation and sponsorship of the National Cancer Institute, Wednesday 18 Oct 2023 at 10:15 in Franciscan C at the Hilton in San Francisco on Union Square. Dr. Deisher will be available in Franciscan A for additional discussions after her presentation. In 2022 68% of largest pharma new drugs in clinical development for oncology go after targets that are already saturated with approved drugs. Despite enormous advances in precision medicine over the past 2+ decades, cancer deaths declined only 5% between 1997 and 2020. AVM’s lead small molecule targets an immune pathway unique from other immunomodulatory drugs and our patient survival is as good as competitors with 82% grade 1 drug-related side-effects and no grade 4 or 5.
